NasdaqCM - Delayed Quote USD
PRF Technologies Ltd. (PRFX)
1.1300 +0.3292 (+41.11%)
At close: January 16 at 4:00:00 PM EST
1.0600 -0.07 (-6.19%)
After hours: January 16 at 7:59:54 PM EST
Chart Range Bar
Loading chart for PRFX
- Previous Close
0.8008 - Open
0.9600 - Bid 0.8260 x 200
- Ask 1.3500 x 200
- Day's Range
0.8769 - 1.5900 - 52 Week Range
0.6110 - 6.6500 - Volume
63,716,494 - Avg. Volume
1,718,800 - Market Cap (intraday)
4.424M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
0.04 - EPS (TTM)
29.9000 - Earnings Date (est.) --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was formerly known as PainReform Ltd. and change its name to PRF Technologies Ltd. in January 2026. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
www.painreform.com2
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PRFX
View More
Performance Overview: PRFX
Trailing total returns as of 1/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
PRFX
76.01%
S&P 500 (^GSPC)
1.38%
1-Year Return
PRFX
65.23%
S&P 500 (^GSPC)
16.89%
3-Year Return
PRFX
96.23%
S&P 500 (^GSPC)
73.54%
5-Year Return
PRFX
99.56%
S&P 500 (^GSPC)
84.17%
Earnings Trends: PRFX
View MoreStatistics: PRFX
View MoreValuation Measures
As of 1/16/2026
Market Cap
4.42M
Enterprise Value
1.00M
Trailing P/E
0.04
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.19%
Return on Equity (ttm)
-127.65%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.09M
Diluted EPS (ttm)
29.9000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.48M
Total Debt/Equity (mrq)
0.66%
Levered Free Cash Flow (ttm)
-4.54M
Compare To: PRFX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
1.1300
+41.11%
Mkt Cap 4.424M
Industry Drug Manufacturers—Specialty & Generic
0.0950
-10.46%
Mkt Cap 12.163M
Industry Drug Manufacturers—Specialty & Generic
1.6300
+10.14%
Mkt Cap 3.136M
Industry Drug Manufacturers—Specialty & Generic
0.3770
-1.31%
Mkt Cap 130.527M
Industry Drug Manufacturers—Specialty & Generic
27.43
-8.75%
Mkt Cap 13.564B
Industry Drug Manufacturers—Specialty & Generic
3.3100
-0.90%
Mkt Cap 403.83M
Industry Drug Manufacturers—Specialty & Generic
Company Insights: PRFX
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.